Amgen, J&J EPO Study Proposals On Tumor Progression To Be Reviewed By Cmte.

The Oncologic Drugs Advisory Committee will discuss the adequacy of the study proposals. The companies maintain that erythropoietin, when used for labeled indications, is not associated with an increased risk of mortality.